| 57.645 -0.435 (-0.75%) | 04-15 11:40 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 70.1 | 1-year : | 72.67 |
| Resists | First : | 60.01 | Second : | 62.22 |
| Pivot price | 59.1  |
|||
| Supports | First : | 56.45 | Second : | 46.96 |
| MAs | MA(5) : | 58.34 |
MA(20) : | 58.79 |
| MA(100) : | 56.2 |
MA(250) : | 49.81 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 19.3 |
D(3) : | 29.9 |
| RSI | RSI(14): 42.5 |
|||
| 52-week | High : | 62.88 | Low : | 41.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BMY ] has closed above bottom band by 12.4%. Bollinger Bands are 18.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 58.65 - 58.94 | 58.94 - 59.23 |
| Low: | 56.88 - 57.18 | 57.18 - 57.48 |
| Close: | 57.6 - 58.07 | 58.07 - 58.55 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Wed, 15 Apr 2026
Patten Group Inc. Invests $1.04 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Wed, 15 Apr 2026
Massachusetts Financial Services Co. MA Increases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Wed, 15 Apr 2026
Is It Too Late To Reassess Bristol Myers Squibb (BMY) After Its Recent Share Price Rebound - Yahoo Finance
Tue, 14 Apr 2026
FDA Setback For Replimune Opdivo Combo Adds Uncertainty To BMY Outlook - simplywall.st
Mon, 13 Apr 2026
Is Bristol-Myers Squibb Company (BMY) Among the 15 Cash-Rich Dividend Stocks to Invest in Right Now - Insider Monkey
Mon, 13 Apr 2026
Bristol Myers Squibb Company $BMY Stock Position Lifted by Burney Co. - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 2,040 (M) |
| Held by Insiders | 2.03e+009 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 31,670 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 392.1 |
| Profit Margin | 14.6 % |
| Operating Margin | 28.1 % |
| Return on Assets (ttm) | 10.2 % |
| Return on Equity (ttm) | 40.4 % |
| Qtrly Rev. Growth | 1.2 % |
| Gross Profit (p.s.) | 1.2963e+011 |
| Sales Per Share | 1.78481e+011 |
| EBITDA (p.s.) | 7.08148e+010 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 14,160 (M) |
| PE Ratio | 16.6 |
| PEG Ratio | 0 |
| Price to Book value | 0.14 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.71 |
| Dividend | 0 |
| Forward Dividend | 2.985e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|